Astria Launches Phase 3 Trial of Navenibart for HAE
Astria Therapeutics, Inc. (NASDAQ:ATXS) has launched the Phase 3 ORBIT-EXPANSE long-term trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein, for the treatment of hereditary angioedema (HAE). Participants who have completed the ALPHA-ORBIT study are eligible to join.
The ORBIT-EXPANSE trial, registered as NCT07204938, follows the successful completion of the pivotal Phase 3 ALPHA-ORBIT trial (NCT06842823). It consists of two parts: a fixed dosing regimen for at least 6 months, followed by a patient-centered flexible dosing period. Eligible participants from the ALPHA-ORBIT trial can continue into the ORBIT-EXPANSE trial, receiving navenibart in Q3M (every 3 months) or Q6M (every 6 months) regimens.
Navenibart targets plasma kallikrein, a key mediator in HAE attacks. Astria Therapeutics, a biopharmaceutical company focused on allergic and immunologic diseases, is developing this therapy to provide relief to people living with HAE. The currently enrolling ALPHA-ORBIT trial can be found on AlphaOrbit.longboat.com, AstriaTrials.com, or clinicaltrials.gov.
The ORBIT-EXPANSE long-term trial aims to evaluate the long-term safety and efficacy of navenibart in HAE patients. Eligible participants from the ALPHA-ORBIT trial are encouraged to continue their participation in this new phase. Astria Therapeutics continues its commitment to developing life-changing therapies for HAE patients.
Read also:
- Is it advisable to utilize your personal health insurance in a publicly-funded medical facility?
- Dietary strategies for IBS elimination: Aims and execution methods
- Benefits, suitable dosage, and safety considerations for utilizing pumpkin seed oil in treating an overactive bladder
- Harmful Medical Remedies: A Misguided Approach to Healing
